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ABSTRACT
Extensive genomic profiling for endometrioid endometrial carcinoma (EEC) 
has pointed to genes and pathways important in uterine development as critical 
mediators of endometrial tumorigenesis. SOX17 is a developmental transcription 
factor necessary for proper endoderm formation that has been implicated as a tumor 
suppressor and shown to modulate WNT signaling. SOX17 mutation analysis in 539 
primary EECs revealed frequent missense and frameshift mutations with an overall 
11.5% mutation rate. More than half the mutations identified were frameshifts (32 
of 62), and the hotspot missense changes, p.Ala96Gly and p.Ser403Ile, were seen 
in 14 tumors. None of the cases with a mutation had a second SOX17 mutation 
or evidence of allelic loss. Immunofluorescence microscopy performed on primary 
samples showed that there were no changes in SOX17 protein expression associated 
with mutation. Low/absent SOX17 staining was significantly associated with advanced 
stage, high tumor grade and reduced recurrence-free survival. Functional assessment 
of the two hotspot missense mutations and three representative frameshift mutations 
showed that SOX17-A96G and SOX17-S403I have transcriptional activities similar 
to SOX17 wild-type (WT), whereas none of the frameshift mutant proteins showed 
transcriptional activity. Forced expression of SOX17-WT, -A96G or -S403I in EC 
cell lines moderately increased β-catenin mediated transcription, which contrasts 
with previous data showing SOX17 is an inhibitor of TCF/β-catenin signaling. The 
proliferation of EC cell lines was expectedly reduced by transfection with SOX17-WT, 
and further reduced by SOX17-A96G and SOX17-S403I. These data implicate SOX17 
mutation as a selected event in EEC, with clear differences between the missense and 
frameshift mutations.
INTRODUCTION
Endometrial cancer (EC) is the most common 
gynecologic malignancy and both the incidence and 
associated mortality of EC are increasing [1]. ECs are 
broadly classified into two groups: about 85% of ECs are 
endometrioid endometrial carcinomas (EECs) and are 
called type I, whereas type II ECs are non-endometrioid 
histology (mainly serous, mixed or clear cell) [2, 3]. 
The genomic landscape of EEC is well established and 
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includes mutations in oncogenes and tumor suppressor 
genes involved in a variety of cancers, as well as genes 
that play distinct roles in the disease [4-8]. Type I tumors 
are frequently mutated in PTEN, PIK3CA, ZFHX3, 
CTCF, MAX, PIK3R1, FBXW7 and CTNNB1, have few 
large somatic copy number alterations (SCNAs) [5], and 
frequently display microsatellite instability (MSI) [9, 10]. 
The most frequently mutated genes in type II tumors are 
TP53, PIK3CA, PTEN, PIK3R1, and PPP2R1A, and these 
tumors have many more SCNAs than type I ECs [5]. EC 
has one of the highest mutation rates among cancers [11], 
and thus many of the less frequently occurring mutations 
require biologic characterization to determine their 
importance in EC. The roles of these genes that are less 
frequently mutated in EEC, in particular those with known 
roles in uterine development, warrant further investigation.
SOX17 is a critical transcription factor that specifies 
endoderm lineages during development [12, 13]. It is 
essential for uterine adenogenesis during development 
and shows high expression in the adult uterus [14, 15]. 
Ectopic expression of SOX family members, and forced 
expression of a mutant form of SOX17 can induce de-
differentiation of somatic tissues [16, 17]. Not surprisingly, 
SOX abnormalities have been associated with cancers 
[18]. SOX17 transcription is repressed in various solid 
tumors through epigenetic and other mechanisms, and it 
has been implicated as a tumor suppressor in EC [19-23]. 
Sequencing efforts by The Cancer Genome Atlas (TCGA) 
identified somatic SOX17 mutations in EECs, including 
two recurrent hotspot missense changes. Here we report 
that frameshift and stop mutations in SOX17 are more 
common in EECs and functionally different than missense 
changes.
RESULTS
Both frameshift and missense mutations 
frequently occur in SOX17 in EEC
SOX17 was sequenced in 539 EECs with 42 
different somatic mutations observed in 62 tumors 
(overall mutation rate = 11.5%, Supplementary Table 1). 
No tumor harbored more than one SOX17 mutation, and 
there was no evidence for loss of heterozygosity (deletion 
of the wild-type allele) in the mutated tumors (data not 
shown). Frequent missense and loss-of-function (LOF) 
mutations were both observed (Figure 1). Thirty-two 
tumors harbored frameshifts, 25 tumors had missense 
mutations, 3 tumors had in-frame indels and 2 tumors 
had nonsense mutations (Supplementary Table 1). The 
two hotspot missense mutations previously identified by 
TCGA for EC [5] were evident: p.Ser403Ile was seen in 
eight tumors and p.Ala96Gly was seen in six tumors. Of 
the 12 different missense changes seen, 10 are predicted to 
have deleterious effects on protein function using Condel 
prediction software [24] (Supplementary Table 1).
The presence of a SOX17 mutation was significantly 
associated with MSI, a hyper-mutated phenotype caused 
by defects in DNA mismatch repair present in ~30% of 
EECs (Supplementary Table 2). Most of the frameshift 
mutations seen were not, however, strand-slippage 
mutations typically associated with MSI. Only four of 
the 26 different frameshifts occurred in repetitive DNA 
sequences (p.E264fs*101, p.P263fs*124, p.R273fs*114, 
and p.P328fs*59, all of which involved C repeats). 
The C repeat mutations were seen in MSI tumors only 
(Supplementary Table 1). Twenty-eight tumors in our 
Figure 1: Pattern of mutations in SOX17 in EECs. Lollipop plots show somatic mutations in SOX17 in 539 EEC samples stratified 
by DNA mismatch repair status (microsatellite instability positive [MSI] and microsatellite stable [MSS] tumors). Inserts show examples of 
Sanger sequencing traces from mutant tumors. Forty-two different mutations were observed in 62 tumors, including the hotspot missense 
changes p.Ala96Gly (observed in MSS and MSI tumors), and p.Ser403Ile (exclusively seen in MSI tumors). A complete description of 
mutations can be found in Supplementary Table 1.
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series have POLE proofreading domain mutations that 
have been associated with an ultra-mutated phenotype (10 
POLE-mutated tumors are MSI and 18 are MSS) [5, 25, 
26]. Only one POLE-mutated tumor harbored a SOX17 
mutation and this mutation was likely not mutational 
noise secondary to the POLE defect since it was not a 
TCT>TAT or TCG>TTG transition [27]. Together these 
data are consistent with SOX17 being under cancer specific 
mutational selection in this tumor type.
SOX17 mutation status was significantly associated 
with tumor grade. Fifty percent of SOX17-mutant tumors 
were grade 2, compared to 33% of SOX17 wild-type 
(WT) tumors (Supplementary Table 2). Mutation status 
was not associated with lymphovascular space invasion or 
Fédération Internationale de Gynécologie et d’Obstétrique 
(FIGO) stage, or with patient age, race and body-mass 
index (Supplementary Table 2). There was no association 
between SOX17 mutation status and outcome (data not 
shown).
Low SOX17 expression is associated with poor 
outcome
To test the hypothesis that SOX17 mutation is 
associated with changes in protein expression we used 
immunofluorescence microscopy to analyze expression in 
Figure 2: Mutated and wild-type tumors display similar SOX17 expression patterns. Photomicrographs show SOX17 
protein levels in one representative SOX17 wild-type (WT) tumor and five tumors harboring different SOX17 mutations. Tumors are 
counter-stained with cytokeratin to show epithelial tissue. SOX17 shows strong nuclear staining in the epithelial components of all tumors, 
regardless of mutation status.
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51 primary EECs (37 wild-type and 14 with mutations). 
The majority (45 of 51) had detectable SOX17 protein. 
The staining pattern was as expected: SOX17 localized 
to cell nuclei, was prominent in the glandular epithelial 
cells and absent in the stromal compartment (Figure 2). 
Consistent with a previous report [23], advanced stage 
tumors were more likely to have low/absent SOX17 
expression (Supplementary Table 3), and tumors with 
low/absent SOX17 staining had significantly reduced 
recurrence-free survival (RFS) (Supplementary Figure 1). 
There was also a significant association between high 
grade tumors (grades 2 and 3) with absent/low SOX17 
expression (Supplementary Table 3). However, there was 
no difference in expression levels between the wild-type 
and mutant cases (Figure 2 and Supplementary Table 3). 
Because SOX17 is a two-exon gene, the transcripts 
from frameshift mutations should escape nonsense-
mediated decay, but we were unable to detect putative 
truncated protein products in most cases because the 
antibody we used for this staining recognizes an epitope 
that is C-terminal to most of the frameshift mutations 
investigated in this experiment (Asp177-Val414). 
Therefore, the comparable expression levels in tumors 
with wild-type SOX17 and those with single N-terminal 
frameshifts are consistent with allelic compensation.
Because SOX17 can be epigenetically silenced 
through promoter methylation we hypothesized that 
those tumors with absent SOX17 expression might have 
hypermethylated promoters [28-30]. Combined bisulfite 
restriction analysis (COBRA) of the 420bp SOX17 
promoter region was performed for five tumors with low/
absent SOX17 expression and four with medium/high 
protein expression. There was very little methylation in 
this region present in these samples, with only one tumor, 
1655T, showing any discernable methylation by COBRA 
(Supplementary Figure 2A). We confirmed sample 1655T 
had some methylated CpG sites by directly sequencing 
TOPO clones from amplified bisulfite converted DNA. We 
found that 3 of 11 of the PCR clones from tumor 1655T 
contained at least one intact restriction site, whereas the 
PCR clones from the COBRA-negative tumor 1484T did 
not contain any intact sites (Supplementary Figure 2B).
SOX17 frameshift and missense mutants have 
different transcriptional activities
To investigate the effects of SOX17 mutations 
on protein function, myc-tagged WT-SOX17 and 
representative SOX17 mutants (A96G, S403I, R115fs, 
L181fs, and P234fs) were expressed in 293T cells and 
three different EC cell lines. Western blot of 293T cells 
transiently transfected with the WT and mutant expression 
constructs showed expression of all five mutants, with 
lower mass bands (smaller protein) in the frameshift mutant 
lanes (Figure 3A). Immunofluorescence microscopy of 
transfected AN3CA cells proved that all mutant proteins 
were localized to the nucleus (Figure 3B), consistent with 
retention of the predicted nuclear localization sequence in all 
of the mutants. SOX17 transcriptional activity was assayed 
using a SOX17-activiated luciferase reporter that harbors 
two compressed SOX-OCT DNA binding sequences (5’ 
CATTGTATGCAAAT 3’) [16] (Supplementary Figure 3). 
Both the SOX17-A96G and SOX17-S403I mutants showed 
transcriptional activities similar to SOX17-WT in 293T 
cells and three different EC cell lines (AN3CA, HEC1A 
and Ishikawa), whereas the frameshift mutations did not 
show any activity above baseline (Figure 3C). To test if 
the frameshift mutant proteins were capable of inhibiting 
transcriptional activity, SOX17-WT was co-transfected 
with the mutant constructs. SOX17-driven transcription was 
not reduced by co-expression with the frameshift mutant 
proteins, indicating that these mutations were not acting as 
dominant negatives (Supplementary Figure 4).
It has been reported that forced expression of 
SOX17 reduces proliferation of cancer cell lines [21, 23, 
31]. To test if the mutations modulated SOX17’s effects 
on proliferation, SOX17-WT, SOX17-A96G and SOX17-
S403I constructs were transfected into four different cell 
lines and the viability was measured daily (Figure 3D). To 
determine if the differences in proliferation were due to 
changes in cell death or growth rate, propdium-iodide cell 
cycle analysis was performed on AN3CA cells transfected 
with EV, SOX17-WT, SOX17-A96G and SOX17-S403I. 
The SOX17-WT and SOX17-mutant expressing cells had 
increased fractions of cells in the G
0
/G1 phase, pointing 
to changes in cell cycle accounting for the differences in 
proliferation (Figure 3E).
SOX17 missense mutations do not affect 
β-catenin expression or activity
SOX17 can be induced by β-catenin and can also 
act as a WNT signaling antagonist in a variety of normal 
and cancerous tissues [32-34]. To explore the ability 
of the SOX17 mutants to repress WNT signaling in EC, 
we used the well-characterized pBAR TCF/β-catenin 
activated luciferase reporter (also called TOPflash) [35]. 
Forced expression of SOX17 repressed β-catenin signaling 
measured by pBAR in SW480 and HCT-116 colorectal 
cancer (CRC) cell lines, consistent with reported data 
[22, 34] (Supplementary Figure 5). However, when the 
same plasmids were transfected into each of three EC 
cell lines, no repression was seen with any of the SOX17-
WT or mutant constructs (Figure 4A). There was also no 
repression caused by transfection of SOX17-WT or mutant 
constructs in EC cell lines co-transfected with a mutant 
form of β-catenin with enhanced stability, indicating that the 
observed differences between EC and CRC cells were not 
due to differences in basal levels of β-catenin (Figure 4B).
To further explore the relationship between SOX17 
and β-catenin in EEC, primary EECs harboring mutations 
in SOX17 or CTNNB1 (the gene that encodes B-catenin) 
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were co-stained for both proteins. There was no evidence 
of enhanced or reduced staining in mutant samples, and 
we did not see evidence for tissue specific co-expression 
or exclusivity of SOX17 and β-catenin in any of the 
specimens examined (Supplementary Figure 6). These 
data may indicate that the cross-talk between SOX17 and 
β-catenin evident in developing tissues and other cancer 
types is not preserved in EC.
DISCUSSION
The SOX17 mutation pattern we observed in EECs 
is consistent with that of a tumor suppressor, in which 
critical regions are perturbed through single amino acid 
substitutions, and nonsense and frameshift mutations 
occur throughout the entire coding sequence. SOX17 has 
been implicated as a tumor suppressor gene in various 
Figure 3: In vitro characterization of SOX17 mutations.  (A) Western blot of 293T cells with forced expression of myc-tagged 
SOX17-WT or mutant protein. Exogenous SOX17 was detected using an anti-myc antibody and total SOX17 was detected using a SOX17 
antibody. The SOX17 frameshift proteins have the expected myc-tagged SOX17 band sizes, but are not detectable with the anti-SOX17 
antibody due to the mutations. Vinculin is loading control. Endogenous SOX17 is evident in all lysates with longer exposure (not shown). 
The endogenous lower mass truncated SOX17 isoform is also detected by the SOX17 antibody [51]. (B) AN3CA cells were transfected with 
myc-tagged SOX17-WT or the indicated SOX17 mutant constructs. Immunofluorescence microscopy shows none of the mutations alter 
SOX17 localization to the cell nucleus. (C) Transcriptional activity of wild-type and mutant SOX17 on a compressed SOX-OCT reporter. 
The ratio of firefly to renilla luciferase is shown, normalized to empty vector (EV). Error bars are standard deviation of biologic triplicates. 
(D) Effects on cell growth. Viability of the indicated cell lines transfected with wild type and mutant SOX17 was measured 24, 48, and 72 
hours after transfection using Cell Titer-Glo assays. Error bars are standard deviation of technical duplicates. Experiments were performed 
in three biologic replicates and one representative trial is shown. Significance determined for each time point by one-way ANOVA (black 
asterisks) and Tukey’s multiple comparison test (colored asterisks indicate comparison to empty vector) * P < 0.5; ** P < 0.01; *** 
P < 0.001. (E) AN3CA cells were transfected with EV, SOX17-WT, SOX17-A96G or SOX17-S403I, and the percentages of cells in 
different stages of the cell cycle was assessed using propidium-iodide staining and flow cytometry. Experiment performed in triplicate with 
10,000 recorded events per condition per trial. Asterisks denote significant differences compared to EV determined by Tukey’s multiple 
comparison test. * P<0.05; ** P< 0.01.
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solid tumors [22, 30, 36, 37], and we argue that the 
mutations we detected occur because of cancer-specific 
selection rather than mutational noise because of the 
small size of the gene, the paucity of SOX17 mutations 
in POLE-mutated tumors and the lack of strand-slippage 
mutations in MSI tumors. However, the absence of any 
cases displaying loss of heterozygosity or multiple SOX17 
mutations (i.e. no second hit mutations), and the functional 
differences between the missense and frameshift mutations 
indicate that the role of SOX17 mutations in EEC is unlike 
classical tumor suppressor genes.
Zhang and colleagues recently used a small number 
of cases to determine that ECs with reduced SOX17 levels 
are significantly more often advanced stage and these 
patients had significantly reduced recurrence-free survival 
[23]. Our findings support the association between SOX17 
expression with advanced EC stage and poor outcome 
(Supplementary Figure 1 and Supplementary Table 3). We 
also identified a significant association between SOX17 
mutation status and tumor grade (Supplementary Table 2). 
This association could in part be explained by the higher 
rate of SOX17 mutation in MSI tumors that are known to 
be more frequently grade 2 tumors [38].
Our functional characterization efforts revealed 
that the hotspot missense mutations, p.Arg96Gly and 
p.Ser403Ile, did not affect SOX17-mediated transcriptional 
activity, but forced expression of SOX17-A96G and 
SOX17-S403I reduced the viability of transfected EC 
cell lines even further than transfection with SOX17-
WT. This result was unexpected, as we hypothesized that 
these mutations would negatively affect SOX17 tumor 
suppressor activity and potentially allow cells to escape 
the reduced proliferation caused by SOX17. It remains to 
be seen if these mutations truly inhibit the proliferation of 
EC in human tumors, or whether this is an artifact of cell 
line models and in vitro culture system.
Interestingly, transfection of the HEC1A and 
Ishikawa EC cell lines with SOX17-WT did not affect 
luciferase driven by pBAR (Figure 4). This is in contrast 
to the SOX17-mediated repression of WNT signaling 
reported by other groups using the same pBAR reporter 
plasmid [23, 39, 40]. SOX17 does not directly interact 
with the reporter, but instead it is an indirect measurement 
of SOX17’s modulation of TCF and β-catenin activity. The 
effects of SOX17 on pBAR activity has been measured 
by multiple investigators in multiple cell types and 
inconsistencies have been described [40]. We speculate 
that there is a fine balance between SOX17’s activation 
and repression of pBAR that is influenced by multiple 
factors including: the induction of SOX17 by β-catenin 
[41], the GSK3β-independent downregulation of β-catenin 
by SOX17 [34, 42], the direct interaction of SOX17, TCF 
and β-catenin [33, 34], the similarity between TCF and 
SOX17 binding motifs [43], the possibility that SOX17-
mediated repression of TCF promoter sites involves 
additional WNT-induced factors other than β-catenin [40], 
and the positive feedback loop mediated by TCF-4 sites 
within the β-catenin promoter [44].
Overall, our identification and characterization 
of both missense and frameshift mutations in SOX17 
expands upon TCGA’s earlier discovery of SOX17 
missense mutations in EC [5]. Our data show that 
half of SOX17 mutations are loss-of-function defects, 
many of which result in loss of transcriptional activity, 
which further highlights the importance of SOX17 in 
endometrial tumorigenesis. Gene-by-gene characterization 
of mutational targets in EC is critical for moving towards 
a comprehensive understanding of the biology of this 
tumor type. Our data link SOX17, a critical regulator of 
development that plays a role in proper formation of the 
uterus with uterine endometrial carcinoma and implicate 
SOX17 as another player involved in EC pathobiology.
MATERIALS AND METHODS
Patient materials
Tumor samples from patients being treated for uterine 
cancer were collected by the Division of Gynecologic 
Oncology, Washington University Medical Center 
(approved protocols HSC 91-0507 and HSC 93-0828), from 
1991-2010. MSI testing was previously performed [45, 
46], using the 5 NCI consensus markers (BAT25, BAT26, 
D2S123, D5S346, and D17S250). POLE proofreading 
domain mutation screening was previously performed [25]. 
Surgical staging and tumor grade was assigned based on the 
basis of FIGO 2009 criteria [47, 48].
Tumor sequencing
Both SOX17 coding exons were sequenced in 539 
EEC samples using a combination of next-generation 
sequencing (NGS) and Sanger methods. Primers and 
conditions are supplied in Supplementary Table 4. All 
variant calls (Sanger and NGS) were sequenced by Sanger 
methods in paired germline DNA to determine somatic 
origin. Targeted deep sequencing library preparation was 
performed using the TruSeq Custom Amplicon Kit v1.5 
(Illumina, San Diego, CA), with amplicons targeting 
both SOX17 exons and the 3’ UTR. Bar-coded and 
amplified specimens were multiplexed and sequencing 
was performed on an Illumina MiSeq® using 250 base 
paired end reads (MiSeq Reagent Kit v2). Variants were 
identified using Miseq ReporterTM software version 2.5.1 
with the GATK variant caller [49, 50].
Sanger sequencing was performed on all tumors for 
a GC-rich 832bp region of exon 2 that was poorly covered 
by the target panel (0 reads in most samples), and for all 
of exon 1 in the 43 tumors that were poorly covered for 
the exon 1 amplicons (<40X average read depth). Sanger 
sequencing was performed for an additional 12 tumors to 
validate the variants detected by targeted deep sequencing.
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Immunofluorescence microscopy
For cell line studies, cells were seeded in 6-well 
plates on coverslips, then transfected with wild-type 
(WT) or mutant SOX17 expression constructs using the 
ProFection® Mammalian Transfection System (Promega, 
Madison, WI). Forty-eight hours after transfection, cells 
were fixed using 3.7% formalin, permeablized with 0.1% 
triton-100, blocked with 4% normal goat serum, then 
stained with indicated primary antibody (and subsequent 
Alexa Fluor-488 secondary antibody) and DAPI. Primary 
tumor sections (4μm thick) were deparaffinized, then 
heated in 10mM sodium citrate buffer (pH 6.0) containing 
0.05% Tween for 20 minutes in an Electric Pressure 
Cooker. Sections were blocked with 2% donkey serum and 
1% BSA then incubated with indicated primary antibodies, 
followed by corresponding secondary antibodies and 
bisbenzimide H 33258 (Hoechst 33258, Sigma-Aldrich, 
St. Louis, MO). Photomicrographs were captured 
using a BZ-9000 microscope (Keyence, Osaka, Japan). 
Microscope settings were not changed between samples 
and SOX17 intensity was scored by blinded researchers 
as absent/low, moderate or high (Supplementary Figure 7).
Viability assay
The indicated cell lines were seeded in opaque 96-
well plates, then transfected with WT or mutant SOX17 
Figure 4: SOX17 does not repress TCF/β-catenin activity in EC.  (A) SOX17 effects in the context of basal TCF/β-catenin-
mediated transcription. Transcriptional activity of the pBAR TCF/β-catenin activity reporter measured in the indicated endometrial cancer 
cell lines after transfection with empty vector (EV), SOX17-wild-type (WT) or the indicated SOX17 mutants. LiCl treatment or transfection 
of a quadruple mutant β-catenin (S33A, S37A, T41A, S45A) with enhanced stability were used as controls to activate the reporter. (B) 
SOX17 effects in the context of elevatedTCF/β-catenin-mediated transcription. Co-transfection of the indicated SOX17 construct (or EV) 
with quadruple mutant β-catenin and the luciferase plasmids was performed in the indicated cell lines. The first lane shows basal reporter 
activity without mutant β-catenin transfection. Firefly to renilla luciferase ratio is reported (normalized to EV). Significance determined by 
Tukey’s multiple comparison test, * P < 0.5; ** P < 0.01; *** P < 0.001.
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expression constructs using Lipofectamine 2000 (Thermo 
Fisher, Waltham, MA). Viability was assessed every 24 
hours using chemiluminescent TiterGlo assays (Promega, 
Madison, WI) from three biological replicates according 
to the manufacturer’s instructions.
Cell cycle analysis
AN3CA cells expressing EV, SOX17-WT, SOX17-
A96G and SOX17-S403I fixed were in ethanol, treated 
with RNAse A and then suspended in propidium iodide. 
Fluorescence-activated cell sorting was performed using 
an LSR II cytometry (Beckman-Coulter, Brea, CA, USA), 
with 10,000 events recorded per condition. Cell cycle 
analysis was performed with the FlowJo software v7.6.3 
(FlowJo LLC, Ashland, OR, USA) using the Watson 
model and no constraints.
COBRA and bisulfite sequencing
Bisulfite conversion of primary tissue DNA was 
performed using EZ DNA Methylation-Gold Kit reagents 
(Zymo Research), Irvine, CA. The SOX17 promoter region 
was amplified as described [30]. Digestion was performed 
with either HhaI or TaqI, then DNA fragments were 
resolved on 10% polyacrylamide gels. PCR products were 
cloned using the PCR-2.1TOPO TA vector (Invitrogen, 
Carlsbad, CA) and sequenced using the M13 reverse primer.
Luciferase reporter assay
Cells were seeded in 12-well plates and transfected 
using Lipofectamine 2000 (Thermo Fisher, Waltham, MA) 
with the indicated expression plasmids (200ng unless 
otherwise indicated), renilla luciferase control plasmid 
(50ng), and a firefly luciferase reporter (200ng unless 
otherwise indicated). Luciferase was measured via the 
Dual-Luciferase Reporter System (Promega, Madison, WI).
Cell culture
293T cells and AN3CA cells were cultured in 
DMEM (Life Technologies, Carlsbad, CA), Hec-1a cells 
were cultured in McCoy’s 5A media (Life Technologies, 
Carlsbad, CA), and Ishikawa cells were cultured in 1:1 
F12:DMEM (Life Technologies, Carlsbad, CA). All cell 
lines were cultured with 10% FBS (Life Technologies, 
Carlsbad, CA). Cell lines used were confirmed to be 
mycoplasma negative using the MycoAlert Mycoplasma 
Detection Kit (Lonza, Basel, Switzerland). Cells were 
obtained from American Type Culture Collection.
Western blotting
Cells were lysed with RIPA buffer, and lysates were 
subjected to sodium dodecyl sulfate- polyacrylamide gel 
electrophoresis followed by nitrocellulose membrane 
transfer. Membranes were blocked with non-fat dry milk, 
and probed with the indicated primary antibody, then 
HRP-conjugated secondary antibody.
Antibodies and plasmids
The following antibodies were used: c-Myc (9E10) 
(sc-40, Santa Cruz Biotechnology, Santa Cruz, CA); 
SOX17 (AF1974, R&D systems, Minneapolis, MN); 
pan-cytokeratin (sc-81714, Santa Cruz Biotechnology, 
Santa Cruz, CA); β-catenin (zymed 13-8400, Thermo 
Fisher, Waltham, MA) vinculin (v4139, Sigma-Aldrich, 
St. Louis, MO); HRP-anti-mouse IgG (NA934V, GE 
Healthcare); Alexa Fluor-488 goat anti-mouse IgG (H+L) 
(A11029, Invitrogen, Carlsbad, CA), Alexa Fluor-488 
donkey anti-goat IgG (H+L) (705-546-147, Jackson 
ImmunoResearch Laboratories, West Grove, PA); Alexa 
Fluor-594 donkey anti-mouse IgG (H+L) (715-586-150, 
Jackson ImmunoResearch Laboratories, West Grove, PA).
The coding sequencing of WT SOX17 was PCR-
amplified from human tumor cDNA synthesized using 
superscript III reverse transcriptase (Thermo Fisher, 
Waltham, MA), and cloned into the pCDH-CMV-MCS-
EF1-GreenPuro plasmid (SystemsBiosciences Palo Alto, 
CA). Mutations were introduced using the QuikChange II 
XL Site-Directed Mutagenesis Kit (Agilent Technologies, 
Santa Clara, CA). A mutant β-catenin (S33A, S37A, 
T41A, S45A) expression construct, SOX17 compressed 
motif reporter [16] and pBAR TCF/β-catenin activated 
reporter [35] were obtained from addgene.
Statistical analysis
P-values for survival were calculated by log-
rank test. Significance for associations between SOX17 
mutation status and clincopathologic and demographic 
variables was calculated by Fisher’s exact tests. Testing 
for associations with SOX17 protein expression was 
performed by dichotomizing variables as follows: low/
absent expression and medium/high expression; SOX17 
mutant and SOX17 wild-type; grade 1 and grade 2/3; 
stage I/II and stage III/IV, and using Fisher’s exact tests 
for significance. For viability assays significance was 
determined for each time point by one-way ANOVA and 
Tukey’s multiple comparison test. For luciferase assays 
shown in Figure 4, significance was determined by 
Tukey’s multiple comparison test between all groups. For 
cell cycle analysis significance was determined by Tukey’s 
multiple comparison test. Calculations were performed 
using Prism 5 (GraphPad Software, La Jolla, CA).
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